Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.

Ploner, F; Jakesz, R; Hausmaninger, H; Kolb, R; Stierer, M; Fridrik, M; Steindorfer, P; Gnant, M; Haider, K; Mlineritsch, B; Tschurtschenthaler, G; Steger, G; Seifert, M; Kubista, E; Samonigg, H; Onkologie. 2003; 26(2):115-119

In vitro studies on the immunosuppressive effect of 2″,2″-difluorodeoxycytidine (dFdC) and its metabolite 2″,2″-difluorodeoxyuridine (dFdU).

Tiefenthaler, M; Hohla, F; Irschick, E; Strasser-Wozak, E; Bacher, N; Mühlmann, O; Wein, W; Konwalinka, G; Immunobiology. 2003; 207(2):149-157

Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.

Schmid, M; Jakesz, R; Samonigg, H; Kubista, E; Gnant, M; Menzel, C; Seifert, M; Haider, K; Taucher, S; Mlineritsch, B; Steindorfer, P; Kwasny, W; Stierer, M; Tausch, C; Fridrik, M; Wette, V; Steger, G; Hausmaninger, H; J CLIN ONCOL. 2003; 21(6): 984-990.

Tetrocarcin-A–induced ER stress mediates apoptosis in B-CLL cells via a Bcl-2–independent pathway.

Anether, G; Tinhofer, I; Senfter, M; Greil, R; BLOOD. 2003; 101(11): 4561-4568.

A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).

Kühr, T; Burgstaller, S; Apfelbeck, U; Linkesch, W; Seewann, H; Fridrik, M; Michlmayr, G; Krieger, O; Lutz, D; Lin, W; Pont, J; Köck, L; Abbrederis, K; Baldinger, C; Buder, R; Geissler, D; Hausmaninger, H; Lang, A; Zabernigg, A; Duba, C; Hilbe, W; Eisterer, W; Fiegl, M; Greil, R; Gastl, G; Thaler, J; Leuk Res. 2003; 27(5):405-411

Tuning the rheostat of the myelopoietic system via Fas and TRAIL.

Greil, R; Anether, G; Johrer, K; Tinhofer, I; CRIT REV IMMUNOL. 2003; 23(4): 301-322.

Significant increase in breast conservation in 16 years of trials conducted by the Austrian Breast & Colorectal Cancer Study Group.

Jakesz, R; Samonigg, H; Gnant, M; Kubista, E; Depisch, D; Kolb, R; Mlineritsch, B; Mischinger, HJ; Menzel, RC; Steindorfer, P; Kwasny, W; Tausch, C; Stierer, M; Taucher, S; Seifert, M; Hausmaninger, H; Ann Surg. 2003; 237(4):55-64

Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools.

Greil, R; Anether, G; Johrer, K; Tinhofer, I; J LEUKOCYTE BIOL. 2003; 74(3): 311-330.

Attenuation of virulence properties of Candida albicans in vitro by basidiomycete metabolites

Pleyer, L; Ressler, S; Berg, A; Wurzner, R; Dierich, MP INT J MED MICROBIOL. 2004; 294: 192-192.

Beacopp Chemotherapy for Advanced Hodgkin’s Disease: Results of Further Analyses of the HD9- and HD12- Trials of the German Hodgkin Study Group (GHSG).

Diehl, V; Brillant, C; Franklin, J; Hermann, R; Greil, R; Engert, A; Pfistner, B; Blood. 2004; 104(11):307–46th Annual Meeting of American Society of Hematology (ASH); 04.-07.12.2004; San Diego, California.